Regeneron price target raised to $850 from $725 at BMO Capital

BMO Capital analyst Evan Seigerman raised the firm’s price target on Regeneron (REGN) to $850 from $725 and keeps an Outperform rating on the shares. Following Regeneron’s itepekimab miss in June, shares have appreciated about 50% as efforts to resolve regulatory uncertainty have started to pay dividends, the analyst tells investors in a research note. BMO adds it is raising its target price as the firm expects higher contributions from Dupixent and more moderate erosion of 2mg Eylea than previously estimated.